Storebrand Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Storebrand Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.5M	Buy	107,628 +5,061	+5%	+$2.24M	0.13%	155
2026 Q1	$45.8M	Sell	102,567 -7,006	-6%	-$3.27M	0.13%	153
2025 Q4	$49.7M	Sell	109,573 -2,295	-2%	-$989K	0.13%	150
2025 Q3	$43.8M	Buy	111,868 +3,585	+3%	+$1.5M	0.12%	173
2025 Q2	$48.2M	Buy	108,283 +7,163	+7%	+$3.3M	0.14%	149
2025 Q1	$49M	Sell	101,120 -33,931	-25%	-$15.8M	0.16%	134
2024 Q4	$54.4M	Sell	135,051 -5,916	-4%	-$2.74M	0.17%	125
2024 Q3	$65.6M	Sell	140,967 -14,314	-9%	-$6.88M	0.21%	112
2024 Q2	$72.8M	Buy	155,281 +2,294	+1%	+$996K	0.24%	94
2024 Q1	$64M	Sell	152,987 -5,154	-3%	-$2.18M	0.22%	108
2023 Q4	$64.3M	Buy	158,141 +5,910	+4%	+$2.18M	0.23%	101
2023 Q3	$52.9M	Buy	152,231 +4,158	+3%	+$1.45M	0.25%	94
2023 Q2	$52.1M	Sell	148,073 -20,105	-12%	-$6.77M	0.24%	107
2023 Q1	$53M	Sell	168,178 -13,205	-7%	-$3.96M	0.27%	97
2022 Q4	$52.4M	Buy	181,383 +13,716	+8%	+$4.18M	0.29%	91
2022 Q3	$48.5M	Buy	167,667 +28,990	+21%	+$8.34M	0.29%	86
2022 Q2	$39.1M	Buy	138,677 +8,942	+7%	+$2.39M	0.22%	112
2022 Q1	$33.9M	Buy	129,735 +40,511	+45%	+$9.61M	0.16%	160
2021 Q4	$19.6M	Sell	89,224 -4,632	-5%	-$901K	0.09%	271
2021 Q3	$17M	Sell	93,856 -7,249	-7%	-$1.42M	0.08%	281
2021 Q2	$20.4M	Sell	101,105 -1,756	-2%	-$367K	0.1%	254
2021 Q1	$22.1M	Sell	102,861 -23,441	-19%	-$5.15M	0.12%	204
2020 Q4	$29.9M	Sell	126,302 -13,854	-10%	-$3.18M	0.18%	134
2020 Q3	$38.1M	Buy	140,156 +11,708	+9%	+$3.23M	0.27%	77
2020 Q2	$37.3M	Buy	128,448 +21,029	+20%	+$5.7M	0.31%	68
2020 Q1	$25.6M	Buy	+107,419	New	+$24.6M	0.27%	89

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Storebrand Asset Management's VRTX Position: Q2 2026 in Review

Storebrand Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 4.9% in Q2 2026, buying an estimated $2.24M and bringing the position to 107,628 shares worth $53.5M. The position accounts for 0.13% of the portfolio, ranked #155.

Storebrand Asset Management first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $72.8M in Q2 2024. 1,663 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Storebrand Asset Management held 107,628 shares of Vertex Pharmaceuticals worth $53.5M as of Q2 2026.
Storebrand Asset Management bought 5,061 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.24M.
Vertex Pharmaceuticals made up 0.13% of Storebrand Asset Management's portfolio in Q2 2026, its #155 holding.
Storebrand Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
Storebrand Asset Management's Vertex Pharmaceuticals position peaked at $72.8M in Q2 2024.
1,663 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Storebrand Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.